Zobrazeno 1 - 10
of 72
pro vyhledávání: '"ZhengYing Pan"'
Autor:
Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi, Wen Zheng, Ningjing Lin, Xiaopei Wang, Meifeng Tu, Yan Xie, Weiping Liu, Zhitao Ying, Chen Zhang, Zhengying Pan, Xi Wang, Ning Ding, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)
Abstract Background Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma and associated with poor outcomes. The activation status of T cell receptor (TCR) signaling has recently become a focus of attention in
Externí odkaz:
https://doaj.org/article/25c3629a1d384e438702a199c33a1a2e
Publikováno v:
Journal of Medicinal Chemistry. 66:4979-4998
Publikováno v:
RSC medicinal chemistry. 13(8)
Guest editors Keriann Backus, Zhengying Pan and Lyn Jones introduce the themed collection on Covalent Drug Discovery.
Publikováno v:
Journal of Medicinal Chemistry. 65:7278-7295
Fibroblast growth factor receptor 4 (FGFR4) has been identified as a potential target for the treatment of hepatocellular carcinoma (HCC) with aberrant FGFR4 signaling because of its important role in HCC progression and development. Several FGFR4 in
Publikováno v:
European Journal of Medicinal Chemistry. 256:115460
Publikováno v:
Chemical Communications. 58:4901-4904
Although extracellular regulated protein kinases (ERKs) are considered important targets for the treatment of various cancers, the occurrence of severe side effects in clinical trials restricts the development of ERK inhibitors. Here, we developed th
Publikováno v:
Chinese Chemical Letters. :108455
Publikováno v:
Chemical Communications. 56:1521-1524
Tremendous advancements in proteolysis targeting chimera (PROTAC) technology have been made in recent years. However, whether a covalent inhibitor-based PROTAC can be developed remains controversial. Here, we successfully developed chimeric degraders
Publikováno v:
SSRN Electronic Journal.
Publikováno v:
Bioorganicmedicinal chemistry letters. 60
PES (2-phenylethynesulfonamide, pifithrin-μ, PFTμ) is an electrophilic compound that exhibits anticancer properties, protects against chemotherapy-induced peripheral neuropathy in chemotherapy, and shows immunomodulatory, anti-inflammatory and anti